Evidence map›Paper›PMID 32799857›Full record

ArticleMalaria journal2020

Effectiveness of the innovative 1,7-malaria reactive community-based testing and response (1, 7-mRCTR) approach on malaria burden reduction in Southeastern Tanzania.

Yeromin P Mlacha, Duoquan Wang, Prosper P Chaki, Tegemeo Gavana, Zhengbin Zhou, Mihayo G Michael, Rashid Khatib, Godlove Chila, Hajirani M Msuya, Exavery Chaki and 15 more

Abstract read
In one paragraph

Article in Malaria journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Yeromin P MlachaIfakara Health Institute, P. O. Box 78378, Kiko Avenue, Mikocheni, Dar es Salaam, Tanzania.ORCID https://orcid.org/0000-0001-8879-7066
Duoquan WangNational Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention, 207 Rui Jin Er Road, Shanghai, 200025, People's Republic of China.
Prosper P ChakiIfakara Health Institute, P. O. Box 78378, Kiko Avenue, Mikocheni, Dar es Salaam, Tanzania. pchaki@ihi.or.tz.
Tegemeo GavanaIfakara Health Institute, P. O. Box 78378, Kiko Avenue, Mikocheni, Dar es Salaam, Tanzania.
Zhengbin ZhouNational Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention, 207 Rui Jin Er Road, Shanghai, 200025, People's Republic of China.
Mihayo G MichaelIfakara Health Institute, P. O. Box 78378, Kiko Avenue, Mikocheni, Dar es Salaam, Tanzania.
Rashid KhatibIfakara Health Institute, P. O. Box 78378, Kiko Avenue, Mikocheni, Dar es Salaam, Tanzania.
Godlove ChilaIfakara Health Institute, P. O. Box 78378, Kiko Avenue, Mikocheni, Dar es Salaam, Tanzania.
Hajirani M MsuyaIfakara Health Institute, P. O. Box 78378, Kiko Avenue, Mikocheni, Dar es Salaam, Tanzania.
Exavery ChakiIfakara Health Institute, P. O. Box 78378, Kiko Avenue, Mikocheni, Dar es Salaam, Tanzania.
Christina MakunguIfakara Health Institute, P. O. Box 78378, Kiko Avenue, Mikocheni, Dar es Salaam, Tanzania.
Kangming LinGuangxi Center for Disease Control and Prevention, Nanning, China.
Ernest TamboHigher Institute of Health Sciences, Université des Montagnes, Bangangté, BP 208, Cameroon.
Susan F RumishaNational Institute for Medical Research (NIMR), P.O. Box 9653, Dar es Salaam, Tanzania.
Sigsbert MkudeIfakara Health Institute, P. O. Box 78378, Kiko Avenue, Mikocheni, Dar es Salaam, Tanzania.
Muhidin K MahendeIfakara Health Institute, P. O. Box 78378, Kiko Avenue, Mikocheni, Dar es Salaam, Tanzania.
Frank ChackyNational Malaria Control, Ministry of Health, Community Development, Gender, Elderly and Children, Dodoma, Tanzania.
Penelope VounatsouSwiss Tropical and Public Health Institute, Basel, Switzerland.
Marcel TannerSwiss Tropical and Public Health Institute, Basel, Switzerland.
Honorati MasanjaIfakara Health Institute, P. O. Box 78378, Kiko Avenue, Mikocheni, Dar es Salaam, Tanzania.
Maru AregawiThe Global Malaria Programme (GMP), World Health Organization, Geneva, Switzerland.
Ellen HertzmarkDepartment of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Ning XiaoNational Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention, 207 Rui Jin Er Road, Shanghai, 200025, People's Republic of China.
Salim AbdullaIfakara Health Institute, P. O. Box 78378, Kiko Avenue, Mikocheni, Dar es Salaam, Tanzania.
Xiao-Nong ZhouNational Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention, 207 Rui Jin Er Road, Shanghai, 200025, People's Republic of China.ORCID http://orcid.org/0000-0003-1417-8427

Funding

Department for International Development GHSP-CS-OP4-D02World Health Organization 001
6 · The paper itself

Abstract

backgroundIn 2015, a China-UK-Tanzania tripartite pilot project was implemented in southeastern Tanzania to explore a new model for reducing malaria burden and possibly scaling-out the approach into other malaria-endemic countries. The 1,7-malaria Reactive Community-based Testing and Response (1,7-mRCTR) which is a locally-tailored approach for reporting febrile malaria cases in endemic villages was developed to stop transmission and Plasmodium life-cycle. The (1,7-mRCTR) utilizes existing health facility data and locally trained community health workers to conduct community-level testing and treatment.

methodsThe pilot project was implemented from September 2015 to June 2018 in Rufiji District, southern Tanzania. The study took place in four wards, two with low incidence and two with a higher incidence. One ward of each type was selected for each of the control and intervention arms. The control wards implemented the existing Ministry of Health programmes. The 1,7-mRCTR activities implemented in the intervention arm included community testing and treatment of malaria infection. Malaria case-to-suspect ratios at health facilities (HF) were aggregated by villages, weekly to identify the village with the highest ratio. Community-based mobile test stations (cMTS) were used for conducting mass testing and treatment. Baseline (pre) and endline (post) household surveys were done in the control and intervention wards to assess the change in malaria prevalence measured by the interaction term of 'time' (post vs pre) and arm in a logistic model. A secondary analysis also studied the malaria incidence reported at the HFs during the intervention.

resultsOverall the 85 rounds of 1,7-mRCTR conducted in the intervention wards significantly reduced the odds of malaria infection by 66% (adjusted OR 0.34, 95% CI 0.26,0.44, p < 0001) beyond the effect of the standard programmes. Malaria prevalence in the intervention wards declined by 81% (from 26% (95% CI 23.7, 7.8), at baseline to 4.9% (95% CI 4.0, 5.9) at endline). In villages receiving the 1,7-mRCTR, the short-term case ratio decreased by over 15.7% (95% CI - 33, 6) compared to baseline.

conclusionThe 1,7-mRCTR approach significantly reduced the malaria burden in the areas of high transmission in rural southern Tanzania. This locally tailored approach could accelerate malaria control and elimination efforts. The results provide the impetus for further evaluation of the effectiveness and scaling up of this approach in other high malaria burden countries in Africa, including Tanzania.

Indexed as

AntimalarialsCommunicable Disease ControlCommunity Health WorkersHealth FacilitiesHumansIncidenceMalariaPilot ProjectsPrevalenceRural PopulationTanzaniaAntimalarials1,7-mRCTR approachCommunity-basedControlHealth facilitiesInterventionMalariaResponseSurveillanceTestingTreatment

Identifiers

PMID32799857
PMCPMC7429894

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.